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Erythrodermic Dermatomyositis
Huyenlan Nguyen, DO, Joshua Levin, MD and Stephen M. Purcell, DO
Lehigh Valley Health Network, Allentown, Pennsylvania

Case Presentation:

Discussion:

Patient: 50 year-old Caucasian male.
History of Present Illness: This patient presented with
a 15-week history of a rash over his entire body. The rash is associated
with pruritus and edema. Prior treatments include prednisone, hydroxyzine,
cetirizine, famotidine, and triamcinolone with some improvement. He
reports odynophagia, unintentional 10 pound weight loss within the last
3-4 months, and occasional difficulty lifting both arms. He denied nausea,
vomiting, headaches, changes in urinary patterns, and back pain.

Fig. 1

Figure 1: Heliotrope Rash.

Figure 1: Heliotrope rash.

Medical History/Surgical History: Hypothyroidism,
sleep apnea, inguinal hernia repair
Family History: Hypertension, amyotrophic lateral sclerosis
Medications: Levothyroxine

Fig. 4a (10x)

Previous Treatment: Prednisone, hydroxyzine, cetirizine,
famotidine, triamcinolone 0.1% ointment
Current Treatment: Prednisone, hydroxychloroquine,
mycophenolate mofetil, clobetasol 0.05% ointment
Physical Examination: Generalized erythematous patches
on the extensor surfaces of the upper extremities and most of the trunk.
There is confluent erythema and edema of the lower extremities with
sparing of the popliteal fossa and lateral feet. Scaly erythematous papules
and patches on the dorsal hands with distinct flat-topped papules over the
PIP and DIP joints and dorsal toes. Erythema and edema on face, ears, and
the upper eyelids. There is hyperkeratosis and prominent telangiectatic
vessels in the proximal nail folds with ragged cuticles. There is a palpable
1cm lymph node in the right axilla. Genitals are spared. No muscle
weakness on initial exam.
Laboratory Data: (9/19/2014) Creatinine kinase 1148 (<351),
AST 104 (<41), ALT 57 (<56), Aldolase 16.3 (1.5-8.1), ANA negative;
(7/17/14) UA, urine porphyrins, serum complement, ACE, ESR, CRP, HLB27 and creatine kinase WNL. Anti-thyroglobulin Ab 42 (0-40), anti-thyroid
peroxidase Ab 337(0-34); (05/24/14) CMP, uric acid, RF, ESR, TSH and CBC
WNL except lymphocyte count 0.79(1.2-4.8)
Studies: MRI brain, CT scan of head/neck, chest, and abdomen were
negative for underlying malignancy (10/10/14). Colonoscopy, endoscopy
(10/2/14), PFT (10/14/14), and left inguinal node biopsy (9/30/14) were
negative for malignancy.
Biopsy: CBL Path (D14NY1-0234678, 08/15/14) Left 3rd finger
dorsal DIP, right knee: Interface dermatitis. “Mild acanthosis and patchy
parakeratoisis with sparse perivascular infiltrate”. Left arm- Punch DIF:
Granular deposition of IgG in epidermis and C3 in BMZ.

Fig. 2

Figure 4a: Magnification 10x- Mild acanthosis and
patchy parakeratosis with sparse perivascular infiltrate.

Figure 2: Erythema of the hands with Gottron’s
papules along the DIP joints and ragged cuticles.

Fig. 3

Figure 3: Erythroderma of the neck and trunk.

Fig. 4b (20x)

Figure 4b: Magnification 20x.

Dermatomyositis (DM) is an autoimmune systemic disease that can involve
the skin, musculoskeletal, gastrointestinal, cardiac and pulmonary systems.
Pathognomonic cutaneous features include the heliotrope rash and Gottron’s
papules. Gottron’s papules are flat-topped erythematous papules and
plaques typically found on joints of the hands and elbows. Poikiloderma, malar
erythema, periungual telangiectasia, and photosensitivity are other common
characteristic findings. Dystrophic and ragged cuticles, known as Samitz sign,
can be observed. Proximal muscle weakness may occur before, during, or after
the presence of cutaneous findings. Systemic manifestations can present as
arthralgia, arthritis, dyspnea, dysphagia, arrhythmia, and dysphonia.
Laboratory studies may yield an elevated creatine kinase, aldolase, aspartate
aminotransferase or lactic dehydrogenase due to myositis. A positive
antinuclear antibody result is common but not diagnostic. Several myositisspecific antibodies have been identified but are not routinely used in diagnosis.
They may, however, aid in the classification of DM subtypes for prognosis. AntiMi-2 antibody is highly specific and is associated with acute-onset classic DM
with a relatively good prognosis. Anti–Jo-1 antibodies are more common in
patients with polymyositis and can be associated with interstitial lung disease,
Raynaud phenomenon, and arthritis. Juvenile onset DM has the best prognosis
for survival, while paraneoplastic DM has the worst prognosis. A malignancy
work up should be performed in all patients with adult onset DM. Multiple
associated malignancies have been reported, including ovarian and breast
cancer in women and lung cancer in men.
Erythroderma is an uncommon presentation of DM and can be associated
with an underlying malignancy. Documented cases include erythrodermic DM
associated with gastric cancer, liver cancer, and adenocarcinoma. Our patient
with erythrodermic DM has had a negative malignancy work up to date. After
3 months on mycophenolate mofetil, hydroxychloroquine, prednisone, and
topical clobetasol, he has cleared significantly. He occasionally experiences
musculoskeletal pain but no longer experiences weakness.
Laboratory studies, malignancy work up, referral to appropriate specialists,
and treatment to control cutaneous and muscle disease are important in
the management of DM. Treatment options include topical and systemic
corticosteroids, antimalarial agents, and immunomodulators. Systemic
corticosteroids has been first line in the treatment of muscle disease.
Methotrexate, mycophenolate mofetil, or azathioprine can be used as steroidsparing agents. Sun avoidance and sun protection are important to avoid
further exacerbations of skin disease.
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